文献速递物质与行为成瘾会诊联络精神医学

整合体重管理的戒烟干预对严重精神疾病成人的随机临床试验

Effect of a Tobacco Cessation Intervention Incorporating Weight Management for Adults With Serious Mental Illness: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2023-01-01

这项随机临床试验纳入192名每日吸烟的严重精神疾病成人,评估18个月药物与行为戒烟干预(含体重管理)的效果。干预组18个月生化验证戒烟率为26.4%,对照组为5.7%(调整OR 5.9,95%CI 2.3-15.4,P<.001),且未导致显著体重增加。

要点

  • 整合体重管理的18个月戒烟干预显著提高严重精神疾病患者长期戒烟率。
  • 干预组18个月戒烟率26.4% vs 对照组5.7%,调整OR 5.9(95%CI 2.3-15.4)。
  • 干预未导致显著体重增加(平均体重变化差异1.6 kg,95%CI -1.5至4.7 kg)。

核心结论

  • 在6个月内有意戒烟的严重精神疾病患者中,18个月一线药物联合行为支持及体重管理的干预可提高烟草戒断率且不显著增重。

研究设计与样本

  • 随机临床试验,2016年7月25日至2020年3月20日在4个社区健康项目开展,纳入192名每日吸烟的严重精神疾病成人,按1个月或6个月内戒烟意愿分层,评估者设盲。

主要发现

  • 18个月时干预组26.4%参与者(27/97,27.8%)达到生化验证7天时点戒烟,对照组5.7%(6/95,6.3%),调整OR 5.9(95%CI 2.3-15.4,P<.001)。
  • 1个月内戒烟意愿未显著改变干预对戒断的效果。
  • 干预组体重增加未显著高于对照组(平均体重变化差异1.6 kg,95%CI -1.5至4.7 kg)。

关键数值与推荐

  • 主要结局为18个月时生化验证的7天时点烟草戒断率。

临床怎么用

  • 对有意戒烟的严重精神疾病成人,可提供一线药物联合行为支持及体重管理的长期综合干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Tobacco smoking drives markedly elevated cardiovascular disease risk and preventable death in persons with serious mental illness, and these risks are compounded by the high prevalence of overweight/obesity that smoking cessation can exacerbate. Guideline-concordant combined pharmacotherapy and behavioral smoking cessation treatment improves abstinence but is not routinely offered in community settings, particularly to those not seeking to quit smoking immediately. OBJECTIVE: To determine the effectiveness of an 18-month pharmacotherapy and behavioral smoking cessation intervention incorporating weight management and support for physical activity in adults with serious mental illness interested in quitting smoking within 1 or 6 months. DESIGN, SETTING, AND PARTICIPANTS: This was a randomized clinical trial conducted from July 25, 2016, to March 20, 2020, at 4 community health programs. Adults with serious mental illness who smoked tobacco daily were included in the study. Participants were randomly assigned to intervention or control, stratified by willingness to try to quit immediately (within 1 month) or within 6 months. Assessors were masked to group assignment. INTERVENTIONS: Pharmacotherapy, primarily varenicline, dual-form nicotine replacement, or their combination; tailored individual and group counseling for motivational enhancement; smoking cessation and relapse prevention; weight management counseling; and support for physical activity. Controls received quitline referrals. MAIN OUTCOME AND MEASURES: The primary outcome was biochemically validated, 7-day point-prevalence tobacco abstinence at 18 months. RESULTS: Of the 298 individuals screened for study inclusion, 192 enrolled (mean [SD] age, 49.6 [11.7] years; 97 women [50.5%]) and were randomly assigned to intervention (97 [50.5%]) or control (95 [49.5%]) groups. Participants self-identified with the following race and ethnicity categories: 93 Black or African American (48.4%), 6 Hispanic or Latino (3.1%), 90 White (46.9%), and 9 other (4.7%). A total of 82 participants (42.7%) had a schizophrenia spectrum disorder, 62 (32.3%) had bipolar disorder, and 48 (25.0%) had major depressive disorder; 119 participants (62%) reported interest in quitting immediately (within 1 month). Primary outcome data were collected in 183 participants (95.3%). At 18 months, 26.4% of participants (observed count, 27 of 97 [27.8%]) in the intervention group and 5.7% of participants (observed count, 6 of 95 [6.3%]) in the control group achieved abstinence (adjusted odds ratio [OR], 5.9; 95% CI, 2.3-15.4; P < .001). Readiness to quit within 1 month did not statistically significantly modify the intervention's effect on abstinence. The intervention group did not have significantly greater weight gain than the control group (mean weight change difference, 1.6 kg; 95% CI, -1.5 to 4.7 kg). CONCLUSIONS AND RELEVANCE: Findings of this randomized clinical trial showed that in persons with serious mental illness who are interested in quitting smoking within 6 months, an 18-month intervention with first-line pharmacotherapy and tailored behavioral support for smoking cessation and weight management increased tobacco abstinence without significant weight gain. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02424188.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Daumit GL, Evins AE, Cather C, et al. Effect of a Tobacco Cessation Intervention Incorporating Weight Management for Adults With Serious Mental Illness: A Randomized Clinical Trial. JAMA Psychiatry. 2023. PMID: 37378972. doi:10.1001/jamapsychiatry.2023.1691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。